Therefore, the combination of these established biomarkers with HMGB1 and/or the HMGB1/sRAGE ratio may improve such detection, thereby leading to earlier diagnosis and resulting in better prognosis for patients with ovarian cancer. Here, HMGB1 is linked to ovarian cancer.